Wave Life Sciences Ltd. Q1 FY2026 earnings call

• Accelerating development of WVE007 for obesity, with Phase 2A trial preparation. - RNA editing program WVE006 showing potential in AATD with Restoration 2 trial data. - Advancing WVE008 for PNPLA3 liver disease. - Proprietary chemistry translating in the clinic. - Pipeline of next generation candidates.

Revenue for the first quarter of 2026 was $38.2 million. Research and development expenses were $47.4 million. G&A expenses were $22.1 million. Net loss was $26.1 million. Ended the first quarter with $544.6 million in cash to cash equivalents. WVE007 is rapidly advancing with Phase 2A trial preparation. WVE006's Restoration 2 trial shows potential for AATD. WVE008 is progressing towards the clinic.

• Cash to cash equivalents will be sufficient to fund operations into the third quarter of 2028. - Rapidly advancing multiple studies of WVE007. - Delivering new WVE006 data in May. - Progressing WVE008 towards the clinic.

Includes questions from various analysts about topics like optimizing trial design for WVE007, regulatory interactions for WVE006, dose selection and GLP-1 use in WVE007's Phase 2A, competitive landscape, data cadence for WVE006, regulatory thresholds for WVE007, NHEB-AE poster, competitive landscape for obesity, dosing regimen of WVE006, MRI PDFF reduction in WVE007's Phase IIa, tissue penetration of DMD program, and maintenance phase with GLP-1